MXCT

MaxCyte (MXCT)

MaxCyte Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MXCT

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/29	21 : 05	GlobeNewswire Inc.	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference	NASDAQ:MXCT	MaxCyte Inc
2024/05/22	21 : 05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development	NASDAQ:MXCT	MaxCyte Inc
2024/05/08	06 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MXCT	MaxCyte Inc
2024/05/08	05 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/05/08	05 : 05	GlobeNewswire Inc.	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance	NASDAQ:MXCT	MaxCyte Inc
2024/04/10	21 : 05	GlobeNewswire Inc.	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024	NASDAQ:MXCT	MaxCyte Inc
2024/04/02	21 : 05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)	NASDAQ:MXCT	MaxCyte Inc
2024/03/13	05 : 05	GlobeNewswire Inc.	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	NASDAQ:MXCT	MaxCyte Inc
2024/03/06	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/03/05	07 : 39	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2024/03/05	06 : 05	GlobeNewswire Inc.	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	NASDAQ:MXCT	MaxCyte Inc
2024/02/27	06 : 22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:MXCT	MaxCyte Inc
2024/02/15	06 : 26	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2024/02/15	02 : 25	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:MXCT	MaxCyte Inc
2024/02/09	22 : 05	GlobeNewswire Inc.	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	NASDAQ:MXCT	MaxCyte Inc
2024/02/02	06 : 25	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2024/01/31	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2024/01/30	22 : 05	GlobeNewswire Inc.	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers	NASDAQ:MXCT	MaxCyte Inc
2024/01/27	06 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/01/27	01 : 49	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:MXCT	MaxCyte Inc
2024/01/23	22 : 05	GlobeNewswire Inc.	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	NASDAQ:MXCT	MaxCyte Inc
2024/01/09	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2024/01/09	06 : 05	GlobeNewswire Inc.	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:MXCT	MaxCyte Inc
2024/01/05	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2024/01/03	22 : 05	GlobeNewswire Inc.	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline	NASDAQ:MXCT	MaxCyte Inc
2024/01/02	16 : 00	GlobeNewswire Inc.	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director	NASDAQ:MXCT	MaxCyte Inc
2023/12/29	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc
2023/12/12	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MXCT	MaxCyte Inc
2023/12/12	06 : 05	GlobeNewswire Inc.	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023	NASDAQ:MXCT	MaxCyte Inc
2023/12/07	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MXCT	MaxCyte Inc